Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from BioCardia ( (BCDA) ) is now available.
On September 18, 2025, BioCardia announced promising results from the CardiAMP Cell Therapy in Chronic Myocardial Ischemia Trial. The trial’s open label roll-in cohort showed that the therapy was well tolerated and led to significant improvements in exercise tolerance and a reduction in angina episodes at the six-month mark. These results suggest that CardiAMP Cell Therapy could address the unmet needs of patients with chronic myocardial ischemia and refractory angina, potentially enhancing BioCardia’s position in the cardiovascular therapeutics market.
The most recent analyst rating on (BCDA) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on BioCardia stock, see the BCDA Stock Forecast page.
Spark’s Take on BCDA Stock
According to Spark, TipRanks’ AI Analyst, BCDA is a Neutral.
BioCardia’s overall stock score is low due to significant financial challenges, negative technical indicators, and poor valuation metrics. While there are positive developments in clinical trials and regulatory progress, these are overshadowed by financial instability and bearish market momentum.
To see Spark’s full report on BCDA stock, click here.
More about BioCardia
BioCardia, Inc., headquartered in Sunnyvale, California, is a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. The company develops biotherapeutic platforms including CardiAMP autologous and CardiALLO allogeneic cell therapies, with three cardiac clinical stage product candidates in development.
Average Trading Volume: 324,428
Technical Sentiment Signal: Sell
Current Market Cap: $8.92M
For an in-depth examination of BCDA stock, go to TipRanks’ Overview page.